Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Author(s): Aditya Bardia, MD, PhD¹; Ian E. Krop, MD, PhD^2,3; Takahiro Kogawa, MD, PhD⁴; Dejan Juric, MD¹; Anthony W. Tolcher, MD^5,6,7; Erika P. Hamilton, MD^8,9; Toru Mukohara, MD, DMedSci¹⁰; Aaron Lisberg, MD¹¹; Toshio Shimizu, MD, PhD^12,13; Alexander I. Spira, MD¹⁴; Junji Tsurutani, MD, PhD¹; Senthil Damodaran, MD, PhD¹⁵; Kyriakos P. Papadopoulos, MD¹⁶; Jonathan Greenberg, MD, MA, BA^17,18; Fumiaki Kobayashi, PhD, MS²²; Hong Zebger-Gong, MD, PhD¹⁸; Rie Wong, BS²⁰; Yui Kawasaki, PhD¹⁷; Tadakatsu Nakamura, MS¹⁹; Funda Meric-Bernstam, MD¹⁵

Source: https://doi.org/10.1200/JCO.23.01909

Dr. Anjan Patel's Thoughts

Datopotamab Deruxtecan is a new ADC that will likely be approved in the near future. The payload is the same as used in Enhertu, but the antibody is directed at TROP2. This report is from the TROPION-pan tumor study and shows a promising ORR in HR+/HER2- MBC. There is reasonable data for this compound in 2L met-NSCLC in the TROPION-LUNG01 study with an improvement in PFS compared to docetaxel of 4.4 vs 3.7 months. Dato also is effective in patients with actionable genetic alterations in the 2L setting. There is also an ongoing study on its use in the 1L setting for met-NSCLC in combination with pembrolizumab and chemotherapy.

PURPOSE

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.

PATIENTS AND METHODS

TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer (BC) or triple-negative BC (TNBC) are reported.

RESULTS

At data cutoff (July 22, 2022), 85 patients (HR+/HER2– BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2– BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2– BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2– BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2– BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2– BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts.

CONCLUSION

In patients with heavily pretreated advanced HR+/HER2– BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

Author Affiliations

¹Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; ²Yale Cancer Center, New Haven, CT; ³Dana-Farber Cancer Institute, Boston, MA; ⁴Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan; ⁵South Texas Accelerated Research Therapeutics, San Antonio, TX; ⁶NEXT Oncology, San Antonio, TX; ⁷Texas Oncology, San Antonio, TX; ⁸Sarah Cannon Research Institute, Nashville, TN; ⁹Tennessee Oncology, PLLC, Nashville, TN; ¹⁰Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; ¹¹Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA; ¹²Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; ¹³Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama, Japan; ¹⁴Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA; ¹⁵Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; ¹⁶Clinical Research, START, San Antonio, TX; ¹⁷Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ; ¹⁸Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany; ¹⁹Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan; ²⁰Global Oncology Clinical Development, Daiichi Sankyo, Co, Ltd, Tokyo, Japan

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Our site participated in this study, where patients were tested for ESR1 mutations via circulating tumor DNA (ctDNA). Those who tested positive were switched to camizestrant (Cami), which demonstrated improved progression-free survival.

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly utilizes the ubiquitin–proteasome system. It was compared to fulvestrant in patients who had received one prior line of hormonal therapy with a CDK4/6 inhibitor. Among patients with ESR1 mutations, Vepdegestrant demonstrated a median progression-free survival (PFS) of 5.0 months versus 2.1 months with fulvestrant. In the overall population, the median PFS was 3.8 months for Vepdegestrant and 3.6 months for fulvestrant, indicating that the drug showed particular efficacy in tumors harboring ESR1 mutations.

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Elinzanitant, a neurokinin-targeted therapy, has been shown to reduce vasomotor symptoms compared to placebo. These symptoms are one of the reasons some of my patients discontinue aromatase inhibitor (AI) therapy, so Elinzanitant presents a promising alternative to help manage these side effects. Additionally, Fezolinetant is already approved and available on the market.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

The INAVO120 trial evaluated inavolisib + palbociclib–fulvestrant vs placebo + palbociclib–fulvestrant in patients with PIK3CA-mutated, HR+/HER2– advanced breast cancer progressing on or shortly after adjuvant endocrine therapy (ET). Inavolisib significantly improved overall survival (OS) (34.0 vs 27.0 mo) and progression-free survival (PFS) (17.2 vs 7.3 mo), with a higher objective response rate (ORR) (62.7% vs 28.0%) and longer DoR (19.2 vs 11.1 mo). Toxicities were manageable but included more hyperglycemia (63.4%), stomatitis (55.3%), GI, and ocular AEs. Bottom line: this triplet sets a new bar for first-line PIK3CA-mutant HR+ MBC, but we’ll need to stay vigilant about metabolic and mucosal side effects as we bring it into practice.

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial

Adding Palbociclib did not help, revealing that there is no need to continue with different hormonal therapy than the one used in first line. It also added more toxicity.